IP Library Granted Patent US 12,128,021
Granted Patent B1
US 12,128,021 · App. 18/643,773 · Granted Oct 29, 2024

Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Inventors: Claire Mégret (Lyons, FR); Hervé Guillard (Villeurbanne, FR); Jean-François Dubuisson (Lyons, FR)
Assignee: Flamel Ireland Limited
A61K31/22A61K9/14A61K9/1676A61K9/5015A61K9/5026A61K9/5042A61K9/5078A61K9/5084A61K31/19
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,128,021
App. No.
18/643,773
Granted
Oct 29, 2024
Kind
B1
Abstract

Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Claims (43)

1. A method of treating a disorder treatable with gamma-hydroxybutyrate in a human subject in need thereof, the method comprising:

initiating a dosage of a pharmaceutical formulation equivalent to 4.5 g of sodium oxybate once per night orally, wherein the pharmaceutical formulation comprises an immediate-release (IR) portion and a modified-release (MR) portion;

up-titrating the once per night dosage in an amount equivalent to 1.5 g of sodium oxybate;

maintaining the up-titrated once per night dosage for at least a week before any further up-titrating; and

ceasing any further up-titrating upon effect.

2. The method of claim 1 , wherein the once per night dosage is increased by an amount equivalent to 1.5 g of sodium oxybate per night to an effective dosage range of an amount equivalent to 6 g to 9 g of sodium oxybate per night.

3. The method of claim 2 , wherein the once per night dosage is increased by an amount equivalent to 1.5 g of sodium oxybate per night to an effective dosage amount equivalent to 6 g of sodium oxybate per night.

4. The method of claim 2 , wherein the once per night dosage is increased by an amount equivalent to 1.5 g of sodium oxybate per night to an effective dosage amount equivalent to 7.5 g of sodium oxybate per night.

5. The method of claim 2 , wherein the once per night dosage of sodium oxybate is increased by an amount equivalent to 1.5 g of sodium oxybate per night to an effective dosage amount equivalent to 9 g of sodium oxybate per night.

6. The method of claim 1 , wherein the up-titrated once per night dosage is maintained for at least two weeks before any further up-titrating occurs.

7. The method of claim 1 , wherein initiating comprises dosing at an amount equivalent to 4.5 g of sodium oxybate for week 1, and then up-titrating to a dosage amount equivalent to 6 g of sodium oxybate once per night dosage for at least weeks 2-3.

8. The method of claim 7 , wherein the method comprises up-titrating to a dosage amount equivalent to 7.5 g of sodium oxybate once per night dosage for at least weeks 4-8.

9. The method of claim 8 , wherein the method comprises up-titrating to a dosage amount equivalent to 9 g of sodium oxybate once per night dosage for at least weeks 9-13.

10. The method of claim 1 , wherein the ceasing comprises maintaining a stable dosage amount equivalent to 6 g, 7.5 g, or 9 g of sodium oxybate once per night orally.

11. The method of claim 1 , wherein the once per night dosage does not change once a dosage amount equivalent to 9 g of sodium oxybate per night is reached.

12. The method of claim 1 , further comprising administering a stimulant to the human patient.

13. The method of claim 1 , wherein doses higher than an amount equivalent to 9 g of sodium oxybate per night are not to be administered to the human patient.

14. A method of treating a disorder treatable with gamma-hydroxybutyrate in a human subject in need thereof, the method comprising:

initiating a dosage of a pharmaceutical formulation equivalent to 4.5 g of sodium oxybate once per night orally, wherein the pharmaceutical formulation comprises an immediate-release (IR) portion and a modified-release (MR) portion; and

up-titrating the once per night dosage to effect in increments equivalent to 1.5 g of sodium oxybate per night;

maintaining each up-titrated once per night dosage for at least one week before any further up-titrating.

15. The method of claim 14 , wherein the effective once per night dosage is equivalent to 6 g of sodium oxybate per night.

16. The method of claim 14 , wherein the effective once per night dosage is equivalent to 7.5 g of sodium oxybate per night.

17. The method of claim 14 , wherein the effective once per night dosage is equivalent to 9 g of sodium oxybate per night.

18. The method of claim 14 , wherein the up-titrating occurs over a period of at least three weeks.

19. The method of claim 14 , wherein the up-titrating occurs over a period of at least five weeks.

20. A method of treating a disorder treatable with gamma-hydroxybutyrate in a human subject in need thereof, the method comprising:

initiating a dosage of a pharmaceutical formulation equivalent to 4.5 g of sodium oxybate once per night orally, wherein the pharmaceutical formulation comprises an immediate-release (IR) portion and a modified-release (MR) portion; and

maintaining the dosage at an amount equivalent to 4.5 g of sodium oxybate once per night for week 1;

up-titrating the dosage to an amount equivalent to 6 g of sodium oxybate once per night; and

maintaining the up-titrated dosage for at least weeks 2-3.

21. The method of claim 20 , further comprising:

further up-titrating the dosage to an amount equivalent to 7.5 g of sodium oxybate once per night; and

maintaining the further up-titrated dosage for at least weeks 4-8.

22. The method of claim 21 , further comprising:

still further up-titrating the dosage to an amount equivalent to 9 g of sodium oxybate once per night; and

maintaining the still further up-titrated dosage for at least weeks 9-13.

23. A method of treating a disorder treatable with gamma-hydroxybutyrate in a human subject in need thereof, the method comprising:

initiating a dosage of a pharmaceutical formulation equivalent to 4.5 g of sodium oxybate once per night orally, wherein the pharmaceutical formulation comprises an immediate-release portion and a modified-release portion; and

up-titrating the once per night dosage to effect in increments equivalent to 1.5 g of sodium oxybate per night at weekly intervals for at least one week.

24. The method of claim 23 , wherein the once per night dosage is increased by an amount equivalent to 1.5 g of sodium oxybate per night at weekly intervals to an effective dosage range of an amount equivalent to 6 g to 9 g of sodium oxybate once per night orally.

25. The method of claim 23 , wherein the titrating occurs over a period of eight weeks.

26. The method of claim 23 , further comprising maintaining a stable dosage amount equivalent to 6 g, 7.5 g, or 9 g of sodium oxybate once per night, wherein the maintaining occurs after the up-titrating.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2024
From: MÉGRET, CLAIRE; GUILLARD, HERVÉ; DUBUISSON, JEAN-FRANÇOIS
To: FLAMEL IRELAND LIMITED
Reel/Frame 068483/0970 →
Continuity (8)
Continuation 17530096 · Nov 18, 2021
Continuation In Part 17178117 · Feb 17, 2021
Continuation In Part 16527633 · Jul 31, 2019
Continuation 16281235 · Feb 21, 2019
Continuation 15655924 · Jul 21, 2017
Provisional Application 62365812 · Jul 22, 2016
Provisional Application 62399413 · Sep 25, 2016
Provisional Application 62474330 · Mar 21, 2017
Cited By (12)
US 12,186,298 US 12,226,377 US 12,226,388 US 12,226,389 US 12,239,625 US 12,257,223 US 12,263,150 US 12,263,151 US 12,303,478 US 12,478,604 US 12,533,314 US 12,551,457